Skip to main content
    C

    Cardiol Therapeutics Inc Class A (CRDL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.15
    +0.01 (+0.88%)

    Market Cap: $143.38M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(18/27)
    Avg Surprise
    +2.77%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.08
    Range$-0.08 - $-0.07
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.10+26.1%
    60d ago$-0.10+26.1%
    30d ago$-0.08+4.6%
    7d ago$-0.080.0%
    Current$-0.08
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.05
    Range$-0.07 - $-0.03
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.05---
    Sep 26EST
    		-$-0.08---
    Jun 26
    Reported Aug 12
    		$-0.04N/A+55.56%Beat+60.0%
    Mar 26
    Reported May 11
    		$-0.05$-0.08+37.53%Beat+48.4%
    Dec 25
    Reported Mar 30
    		$-0.07$-0.11+36.36%Beat+22.2%
    Sep 25
    Reported Nov 13
    		$-0.12$-0.10-20.00%Miss+33.3%
    Jun 25
    Reported Aug 14
    		$-0.10$-0.12+16.67%Beat+0.0%
    Mar 25
    Reported May 13
    		$-0.10$-0.13+23.08%Beat+28.6%
    Dec 24
    Reported Mar 31
    		$-0.09$-0.12+22.88%Beat+0.0%
    Sep 24
    Reported Nov 14
    		$-0.18$-0.11-63.64%Miss-100.0%
    Jun 24
    Reported Aug 12
    		$-0.10$-0.13+23.08%Beat+16.7%
    Mar 24
    Reported May 14
    		$-0.14$-0.10-40.00%Miss-27.3%
    Dec 23
    Reported Mar 26
    		$-0.09$-0.09+0.00%Beat+25.0%
    Sep 23
    Reported Nov 14
    		$-0.09$-0.12+25.00%Beat+30.8%
    Jun 23
    Reported Aug 10
    		$-0.12$-0.12+0.00%Beat-20.0%
    Mar 23
    Reported May 15
    		$-0.11$-0.15+26.67%Beat+21.4%
    Dec 22
    Reported Mar 28
    		$-0.12$-0.15+20.00%Beat-9.1%
    Sep 22
    Reported Nov 10
    		$-0.13$-0.14+7.14%Beat+27.7%
    Jun 22
    Reported Aug 10
    		$-0.10$-0.15+33.33%Beat+33.3%
    Mar 22
    Reported May 16
    		$-0.14$-0.17+17.65%Beat+46.2%
    Dec 21
    Reported Mar 23
    		$-0.11$-0.14+21.43%Beat+26.7%
    Sep 21
    Reported Nov 15
    		$-0.18$-0.18-0.22%Miss-38.2%
    Jun 21
    Reported Aug 17
    		$-0.15$-0.14-7.14%Miss-48.8%
    Mar 21
    Reported May 18
    		$-0.26$-0.14-85.71%Miss-136.4%
    Dec 20
    Reported Mar 31
    		$-0.15$-0.12-25.00%Miss-25.0%
    Sep 20
    Reported Nov 12
    		$-0.13$-0.09-44.44%Miss-42.9%
    Jun 20
    Reported Aug 13
    		$-0.10$0.00N/AMiss+1.0%
    Mar 20
    Reported May 13
    		$-0.11$-0.16+31.25%Beat+15.4%
    Dec 19
    Reported Mar 26
    		$-0.12$-0.13+7.69%Beat-17.9%
    Sep 19
    Reported Nov 11
    		$-0.09$0.00N/AMiss+77.9%
    Jun 19
    Reported Aug 13
    		$-0.10$0.00N/AMiss+59.4%
    Mar 19
    Reported May 8
    		$-0.13$-0.09-44.44%Miss-90.1%
    Dec 18
    Reported Mar 28
    		$-0.10$0.00N/AMiss-259.7%
    Sep 18
    Reported Dec 31
    		$-0.41$0.00N/AMiss-1293.2%
    Jun 18
    Reported Sep 30
    		$-0.25$0.00N/AMiss-699.0%
    Mar 18
    Reported Jun 30
    		$-0.07$0.00N/AMiss-161.1%
    Dec 17
    Reported Mar 31
    		$-0.03$0.00N/AMiss-
    Sep 17
    Reported Dec 31
    		$-0.03$0.00N/AMiss-
    Jun 17
    Reported Sep 30
    		$-0.03$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.03$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-5.68EV/EBITDAN/A
    Price/FCF-7.63xFCF Yield-13.11%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-190.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio5.55xQuick Ratio5.55x
    Trading Statistics
    Beta0.72Avg Volume1.60M
    52-Week High$2.3452-Week Low$0.88

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.26
    SMA 20$1.50
    SMA 50$1.74
    SMA 200$1.29
    EMA 10$1.28
    EMA 20$1.44
    EMA 50$1.56
    EMA 200$1.37

    MACD

    Line: -0.18Signal: -0.14Hist: -0.04

    ADX

    ADX: 37.7+DI: 9.8-DI: 33.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$1.30

    Bollinger Bands

    Upper Band$2.03
    Lower Band$0.96
    %B Position7136%(Upper)
    Band Width0.17

    RSI (14-Day)

    Oversold
    22.1

    Momentum Oscillators

    Stoch %K3.1
    Stoch %D2.0
    Williams %R-95.7
    ROC (10d)-26.3%
    Momentum-0.41
    CCI (20d)-102.3
    MFI (14d)17.2

    Volatility Measures

    ATR (14d)$0.10(9.1%)
    StdDev (20d)0.27
    Hist Vol50.7%(High)

    Volume Flow

    VWAP$1.15
    OBV13.4M
    AD Line-8.2M
    CMF (20d)-0.372

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.44

    Pivot Points

    R3$1.25
    R2$1.23
    R1$1.18
    Pivot Point$1.16
    S1$1.11
    S2$1.09
    S3$1.04

    Advanced Oscillators

    TSI-47.26
    Ultimate Osc25.4
    KST-319.84

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/A$26,777$25,953N/AN/AN/A$33,697N/A$45,236$61,623N/A$47,767
    Gross ProfitN/A$-26,777$-25,953N/AN/AN/A$-33,697N/A$-45,236$-61,623N/A$-47,767
    Operating Expenses$11.28M$9.71M$8.03M$10.18M$7.68M$8.43M$6.91M$14.14M$5.61M$8.34M$8.03M$5.59M
    R&D$4.54M$4.96M$2.74M$4.79M$2.73M$3.76M$2.94M$3.75M$1.98M$3.32M$4.04M$1.90M
    SG&A$6.74M$4.73M$5.26M$5.37M$4.92M$4.65M$5.76M$10.19M$5.03M$5.08M$3.99M$5.08M
    Operating Income$-11,280,341$-9,731,878$-8,030,975$-10,180,100$-7,676,158$-8,429,063$-6,941,650$-14,140,400$-5,656,601$-8,405,480$-8,028,828$-5,635,501
    Interest Income$201,332$200,724$175,209$122,256$180,667$248,269$306,775$201,864$307,409$377,294$448,303$515,538
    Interest Expense$0$1.11M$0$0$678,213$0$0$0$0$774,152$0$0
    Income Before Tax$-8,928,336$-10,846,547$-7,212,569$-9,964,281$-8,354,371$-8,287,653$-5,683,107$-12,728,484$-4,815,950$-9,179,632$-7,637,017$-4,365,209
    Income Tax Expense$0$0$0$0$0$0$0$0$2$-2$0$-1,575,967
    Net Income$-8,642,701$-10,846,547$-7,212,569$-9,964,281$-8,354,371$-8,287,653$-5,683,107$-12,728,484$-4,815,950$-9,179,632$-7,637,017$-4,365,209
    EBITDA$-8,916,790$-10,819,770$-7,186,593$-9,938,730$-8,328,901$-8,262,667$-5,649,411$-12,527,394$-4,770,712$-9,118,009N/A$-4,317,439
    EBIT$-8,928,336$-10,846,547$-7,212,569$-9,964,281$-8,354,371$-8,287,653$-5,683,108$-12,728,484$-4,815,948$-9,179,632$-8,028,828$-4,365,206
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRDL

    News

    Cardiol Therapeutics (TSX:CRDL): Why Is The MAVERIC Trial Getting Bigger?

    Cardiol Therapeutics has decided to expand its pivotal Phase III MAVERIC trial for CardiolRx, a drug candidate for recurrent pericarditis, despite reaching its original enrollment goal. This expansion...

    Kalkine Media•10/14/26•Neutral

    Cardiol Therapeutics Inc. Class A Slides as Bearish Momentum Intensifies: Downside Risk Mounts Amid Sector Weakness and Execution Concerns

    Cardiol Therapeutics Inc. (TSX:CRDL) has experienced a significant stock decline due to weak investor sentiment, broader healthcare sector weakness...

    kalkine.ca•10/13/26•Neutral

    Cardiol Therapeutics Inc. Class A (TSX:CRDL) Slides -5.91% as Investors Reassess Near-Term Catalysts and Risk

    Cardiol Therapeutics Inc. (TSX:CRDL) experienced a 5.91% decline on October 1, 2026, as investors re-evaluated near-term catalysts and risk. The primary focus for investors remains the CardiolRx clinical development...

    kalkine.ca•10/2/26•Somewhat-Bearish

    Revenue per share of Cardiol Therapeutics Inc. Class A – HAN:CT9

    This article provides financial information for Cardiol Therapeutics Inc. Class A (HAN:CT9) on the TradingView platform. It specifically highlights the "Revenue per share" metric for the company. The content also...

    TradingView•10/1/26•Neutral

    Tejara Capital Holds 5.3% Stake in Cardiol Therapeutics (NASDAQ: CRDL), Owning 6.38 Million Shares

    Tejara Capital Ltd has disclosed a 5.3% ownership stake in Cardiol Therapeutics (NASDAQ: CRDL), holding 6,382,551 Class A common shares. This investment is classified as passive...

    Kalkine Media•9/24/26•Somewhat-Bullish

    CRDL Valuation and Fair Value

    P/E
    -5.7x
    P/FCF
    -7.6x
    P/B
    7.8x
    See GNG's fair value

    CRDL Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -190.2%
    FCF yield
    -13.1%

    CRDL Competitors

    CompanyTicker
    Neuronetics IncSTIM
    Repro Med Systems IncKRMD
    Quanterix CorpQTRX
    Nakamoto Inc.NAKA
    Nkarta IncNKTX
    Codexis IncCDXS
    Protara Therapeutics IncTARA
    Molecular Partners AG ADRMOLN

    Sector: Healthcare

    CRDL Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    2
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    CRDL Bull Case vs Bear Case

    Bull case

    • CRDL beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of CRDL's analyst ratings are Buy or Strong Buy.

    CRDL Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    13.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.08
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About CRDL

    Does CRDL pay dividends?

    Cardiol Therapeutics Inc Class A (CRDL) does not currently pay a regular dividend.

    What is CRDL's market cap?

    Cardiol Therapeutics Inc Class A (CRDL) has a market capitalization of $143.38M with a current stock price of $1.15.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In